Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Arthritis, Rheumatoid × sarilumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Ovarian Neoplasms 2 Neoplasms 2 Fallopian Tube Neoplasms 2 Endometrial Neoplasms 2 Triple Negative Breast Neoplasms 1 Recurrence 1 Pathologic Complete Response 1 Neoplasm Metastasis 1 Metastatic Castration-resistant Prostate Cancer 1 Melanoma 1 Mastocytosis, Systemic 1 Lung Neoplasms 1 Hemangiosarcoma 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1 Arthritis, Rheumatoid 1

Interventions

Adalimumab 14 Etanercept 13 Methotrexate 9 tocilizumab 7 golimumab 6 Infliximab 6 tofacitinib 5 Rituximab 5 Tumor Necrosis Factor Inhibitors 4 Abatacept 4 olokizumab 3 Certolizumab Pegol 3 RC-18 2 Nivolumab 2 Antirheumatic Agents 2 veltuzumab 1 upadacitinib 1 secukinumab 1 sarilumab 1 mavrilimumab 1 entecavir 1 baricitinib 1 andecaliximab 1 Vitamin D 1 Surveys and Questionnaires 1 Sulfasalazine 1 Standard of Care 1 Specimen Handling 1 Saline Solution 1 Radioimmunodetection 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03449758 2022-04-28

SariPRO

Sanofi

Phase 4 Completed

84 enrolled 36 charts

Arthritis, Rheumatoid

Data powered by HemOnc (CC BY 4.0) Colophon ⚡